NLRP3-activated BM dendritic cells induced IL1β-dependent immunity and promoted the differentiation of CD4+ T cells into tumor-specific interferon-γ (IFN-γ)-producing T helper 1 (Th1) cells recognizing and eliminating leukemia cells [21]; this suggest that NLRP3-activated immune cells, namely, dendritic cells and Th1 cells, may have a therapeutic immunotherapeutic potential in AML. The gene discussed is NLRP3; the disease is leukemia.